Illumina, Inc. (ILMN) is expanding its TruSight Oncology portfolio with a new version of its flagship cancer research assay, currently under development. The TruSight Oncology 500 v2 (TSO 500 v2) to enable comprehensive genomic profiling (CGP) of tumors will be presented at the annual meeting of the Association of Molecular Pathology in Vancouver, British Columbia, on Nov. 21.One of the customers having early access to TSO 500 v2 emphasized the relevance of the assay’s new features to clinical research labo ...